UB-VV400 / Umoja Biopharma, IASO BIO - LARVOL DELTA

Preclinical Development of UB-VV400, a Surface Engineered Lentiviral Vector for the In Vivo Generation of CD22-Directed CAR T Cells (ASGCT 2025) - "UB-VV400 demonstrated specific and efficient transduction of T cells, which corresponded with the generation of CD22-directed CAR T cells capable of killing both CD22hi and CD22lo tumor cells in vitro and in vivo. Moreover, the administration of rapamycin promoted RACR-mediated enrichment and expansion of CAR T cells in vivo resulting in complete tumor clearance and B-cell depletion. Overall, nonclinical studies of UB-VV400 ± rapamycin demonstrated a favorable safety profile, with no associated adverse events."

CAR T-Cell Therapy • Preclinical • Viral vector • Hematological Malignancies • Immunology • Oncology • CD22 • CD34 • IL15

Umoja Biopharma Announces Appointment of Dr. Luke Walker as Chief Medical Officer (GlobeNewswire) - "Umoja Biopharma, Inc...announced the appointment of Dr. Luke Walker as Chief Medical Officer...He will be responsible for the leadership of Umoja’s clinical, regulatory, and medical functions, including its two clinical stage in vivo CAR T cell programs UB-VV111 and UB-VV400 in B cell malignancies....'Two of Umoja’s VivoVec in vivo CAR T cell therapy programs are open to enrollment, both CD22-targeted UB-VV400 and CD19-targeted UB-VV111. We look forward to sharing initial clinical data in 2025...'"

P1 data • Hematological Malignancies

Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones (GlobeNewswire) - "Umoja Biopharma, Inc...announced the closing of a $100 million Series C financing....The proceeds from this financing will enable Umoja to advance its in vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in multiple oncology and autoimmune clinical studies....'This Series C fundraise demonstrates both the progress and significant potential of Umoja’s in vivo oncology programs including UB-VV400 and UB-VV111'."

Financing • Oncology

Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) - "Umoja Biopharma...announced that Umoja will present two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)....Umoja’s poster presentations will focus on preclinical data of UB-VV400, an off-the-shelf, multidomain fusion (MDF) protein surface engineered lentiviral vector designed to generate CD22-directed CAR T cells in vivo without requiring lymphodepleting chemotherapy, as well as the company’s RACR-induced cytotoxic lymphocytes (iCIL) platform and its potential for increased production and persistence of CAR T cells....In addition to Umoja’s poster presentations, Seattle Children’s Therapeutics, Umoja’s collaboration partner will be presenting early experience data from the ENLIGHTen-01 trial of UB-TT170."

P1 data • Preclinical • Osteosarcoma